主题：PET/CT在恶性肿瘤中的应用 -- 良金百辟

Can J Cardiol. 2007 February; 23(2): 107–119.

CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease – executive summary

Cardiac PET MPI interpretation should be carried out only by physicians and institutions with adequate training and experience.

Class I indications

Pharmacological MPI using PET for the diagnosis of CAD (diagnosis is intended for patients with intermediate pretest likelihood of disease) and/or risk stratification of patients who:

have nondiagnostic, noninvasive imaging tests, or when such a test does not agree with clinical diagnosis (Level B evidence);

may be prone to artifact that could lead to an equivocal result on another test, such as obese patients (Level B evidence);

are unable to exercise, or have left bundle branch block or ventricular pacing (Level B evidence).

Class IIa indications

Pharmacological MPI using PET for the diagnosis of CAD (diagnosis is intended for patients with intermediate pretest likelihood of disease) and/or risk stratification of patients who are able to exercise (Level B evidence);

For diagnosis and risk stratification of patients being considered for high-risk noncardiac surgery who have intermediate clinical risk predictors or mild clinical risk predictors with poor functional capacity (less than four metabolic equivalents) (Level B/C evidence).

Class IIb indications

Exercise PET using MPI for the diagnosis of CAD and/or risk stratification (Level B evidence);

Quantification of myocardial flow to determine the hemodynamic significance of a given coronary stenosis or to diagnose balanced multivessel disease (Level B/C evidence);

Quantification of myocardial flow to define impaired microvascular function (eg, syndrome X) (Level B/C evidence).